[go: up one dir, main page]

DE60228233D1 - Pyruvat-kinase als einem neuen zielmolekül - Google Patents

Pyruvat-kinase als einem neuen zielmolekül

Info

Publication number
DE60228233D1
DE60228233D1 DE60228233T DE60228233T DE60228233D1 DE 60228233 D1 DE60228233 D1 DE 60228233D1 DE 60228233 T DE60228233 T DE 60228233T DE 60228233 T DE60228233 T DE 60228233T DE 60228233 D1 DE60228233 D1 DE 60228233D1
Authority
DE
Germany
Prior art keywords
target molecule
new target
pyruvate kinase
pyruvate
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60228233T
Other languages
English (en)
Inventor
Axel Ullrich
Attila Stetak
Gyorgy Keri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Application granted granted Critical
Publication of DE60228233D1 publication Critical patent/DE60228233D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60228233T 2001-05-23 2002-05-23 Pyruvat-kinase als einem neuen zielmolekül Expired - Lifetime DE60228233D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112601 2001-05-23
PCT/EP2002/005684 WO2002095063A1 (en) 2001-05-23 2002-05-23 Pyruvate-kinase as a novel target molecule

Publications (1)

Publication Number Publication Date
DE60228233D1 true DE60228233D1 (de) 2008-09-25

Family

ID=8177529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228233T Expired - Lifetime DE60228233D1 (de) 2001-05-23 2002-05-23 Pyruvat-kinase als einem neuen zielmolekül

Country Status (10)

Country Link
US (2) US20040152648A1 (de)
EP (2) EP1390525B8 (de)
AT (1) ATE404691T1 (de)
AU (1) AU2002319180B2 (de)
CA (1) CA2448165A1 (de)
DE (1) DE60228233D1 (de)
DK (1) DK1390525T3 (de)
ES (1) ES2312595T3 (de)
PT (1) PT1390525E (de)
WO (1) WO2002095063A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016646A2 (en) * 2002-08-12 2004-02-26 Amynon Bio Tech Gmbh Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk)
US20040235071A1 (en) * 2002-12-20 2004-11-25 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 14218, 33877, 10317, 10485, 25964, 14815, 1363, 1397, 14827, 21708, 3801, 64698, 2179 or 13249
DE10356218A1 (de) * 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
WO2006055880A2 (en) * 2004-11-16 2006-05-26 Genzyme Corporation Diagnostic pkm2 methods and compositions
WO2006065967A2 (en) * 2004-12-15 2006-06-22 General Atomics Allosteric enzyme coupled immunoassay (aecia)
WO2009025781A1 (en) * 2007-08-16 2009-02-26 Beth Israel Deaconess Medical Center Activators of pyruvate kinase m2 and methods of treating disease
EP2344453B1 (de) 2008-10-09 2016-12-28 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Aktivatoren der humanen pyruvatkinase
CN102448951B (zh) 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
CA2760929C (en) 2009-05-04 2018-01-02 Agios Pharmaceuticals, Inc. Pkm2 activators for use in the treatment of cancer
JP5764555B2 (ja) 2009-06-29 2015-08-19 アジオス ファーマシューティカルズ, インコーポレイテッド 治療組成物および関連する使用方法
AR077292A1 (es) 2009-06-29 2011-08-17 Agios Pharmaceuticals Inc Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas
EP2525790B1 (de) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Verfahren und zusammensetzungen für zellproliferationsbedingte erkrankungen
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US9206426B2 (en) 2010-03-05 2015-12-08 The Trustees Of Columbia University In The City Of New York Inhibitory RNAs to RNA binding proteins hnRNPA1, hnRNPA2 and PTB and uses thereof
EP2563761A1 (de) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Aktivatoren der menschlichen pyruvatkinase
CA2821975A1 (en) 2010-12-17 2012-06-21 Shunqi Yan N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
CA2822432C (en) 2010-12-21 2019-09-24 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
EP3406251B1 (de) 2011-05-03 2023-11-29 Agios Pharmaceuticals, Inc. Pyruvatkinaseaktivatoren zur verwendung in der therapie
JP7320339B2 (ja) 2015-06-11 2023-08-03 アジオス ファーマシューティカルズ, インコーポレイテッド ピルビン酸キナーゼ活性化因子を使用する方法
DK3483164T3 (da) 2017-03-20 2020-03-23 Forma Therapeutics Inc Pyrrolopyrrolsammensætninger som pyruvatkinase (pkr) aktivatorer
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
EP3852791B1 (de) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Aktivierung von pyruvatkinase r
BR112022004715A2 (pt) 2019-09-19 2022-06-14 Forma Therapeutics Inc Composições de ativação de piruvato quinase r (pkr)
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
WO1998035032A2 (en) * 1997-02-11 1998-08-13 The Regents Of The University Of California Methods of inducing cell cycle stasis
US7074895B2 (en) * 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
US5948628A (en) * 1997-09-05 1999-09-07 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay

Also Published As

Publication number Publication date
EP1390525A1 (de) 2004-02-25
PT1390525E (pt) 2008-11-25
ES2312595T3 (es) 2009-03-01
DK1390525T3 (da) 2008-12-08
WO2002095063A1 (en) 2002-11-28
US20040152648A1 (en) 2004-08-05
EP1390525B8 (de) 2009-03-04
ATE404691T1 (de) 2008-08-15
CA2448165A1 (en) 2002-11-28
AU2002319180B2 (en) 2007-07-05
EP1990422A1 (de) 2008-11-12
EP1390525B1 (de) 2008-08-13
US20080021116A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
ATE404691T1 (de) Pyruvat-kinase als einem neuen zielmolekül
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
GB0325956D0 (en) Novel compounds
PL1706424T3 (pl) Warianty regionu Fc
SE0202838D0 (sv) Chemical compounds
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
BR0214230A (pt) Compostos e processos de fabricação de compostos
PL366590A1 (en) Novel compounds as anti-inflammatorz, immunomodulatory and anti-proliferatory agents
CL2013002895A1 (es) Compuestos derivados de 7,8-dihidro-5h-pteridin-6-ona, utiles como intermediarios en la sintesis de compuestos derivados de pteridinona (divisional de la solicitud 3123-2005).
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
SE0101082D0 (sv) Novel use
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
WO2003091243A8 (en) Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
ATE334977T1 (de) Discodermolid-analoga und ihre pharmazeutische verwendung
NO20033401L (no) Kjemiske forbindelser
WO2002062297A3 (en) Methods and compositions for modulating gluconeogenesis using pgc-1
BR0211620A (pt) Imidazopiridinas substituìdas por alquila para o tratamento de distúrbios gastrointestinais

Legal Events

Date Code Title Description
8364 No opposition during term of opposition